Navigation Links
Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/6/2008

CAMBRIDGE, Mass., Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 9:30 a.m. ET in the Park Avenue Suite Center/North Room at the Waldorf-Astoria Hotel in New York, NY.

The live and archived webcasts of the presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com or directly linking to http://phx.corporate-ir.net/phoenix.zhtml?p=irol- eventDetails&c=131556&eventID=1752370. (Due to the length of URL, please cut and paste into browser). Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Milwaukee, Wisc. (PRWEB) May 21, 2013 ... equipment parts distributor , will be exhibiting for ... the Advancement of Medical Instrumentation (AAMI) 2013 Conference ... manage, purchase, support, distribute, and manufacture healthcare technologies. ... 1-3 in Long Beach, California. , The ...
(Date:5/21/2013)... 2013 Clinverse, Inc. , ... clinical trials, announced today it has formed a ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship ... and reporting transfer of value at investigator meetings ...
(Date:5/21/2013)... 2013 As the R&D sector ... within the industry to deliver better products, faster. ... pharma companies often means turning big ideas into ... in collaboration with Sensidose AB and Recipharm, is ... products to market sooner. The partnership resulted in ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... - Wisconsin companies raised more venture capital in more deals ... categories, according to report from Ernst & Young, LLP ... Wisconsin reported 12 venture deals in 2006, including a $12 ... maker of genomic research tools, for a total of $58.47 ...
... fully committed, University Research Park in Madison will ... Accelerator 2 facility. , ,Accelerator 2, which will be built ... ready to "graduate" from the MGE Innovation Center, the park's ... size from 2,500 to 5,000 square feet, and should be ...
... Automation's gift of $1 million to the ... the advanced automation industry throughout southeastern Wisconsin, does not ... technology transfer niche, according to the executive director of ... UWM-Rockwell partnership will focus on three areas of ...
Cached Biology Technology:Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3Research park to add accelerator suites 2Rockwell's $1M gift to UWM will support advanced automation research 2Rockwell's $1M gift to UWM will support advanced automation research 3
(Date:5/21/2013)... American Chemical Society (ACS), the world,s largest scientific ... National Meeting & Exposition, September 8-12, 2013, in ... Indiana Convention Center and at area hotels. , ... that span science,s horizons from astronomy to ... and online journalists a rich assortment of spot ...
(Date:5/21/2013)... charted the path of insulin action in cells in ... blueprint for understanding what goes wrong in diabetes. ... Professor David James from Sydney,s Garvan Institute of Medical ... of the prestigious journal Cell Metabolism . , ... very important role in the body because it helps ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... modified mice and rats in combination with an animal model ... researchers new insight in the development of kidney disease. ... International. , "Chronic kidney disease is difficult to study since ... Joost P. Schanstra, Ph.D. of the Instituit Louis Bugnard inFrance. ...
... microscopic fungus built from threadlike filaments. But collectively, these ... nutrients out of the soil and into plants each ... movement of nitrogen brings into sharper focus this underground ... food chains. , "Ignorance (about the movement of nitrogen) ...
... search through human genes has begun at the ... Working within the MitoCheck consortium that includes 10 ... silence all human genes, one-by-one, to find those ... fundamental questions of how cell division is regulated. ...
Cached Biology News:Digging in the dirt for life's biochemical foundations 2Hunt for human genes involved in cell division under way 2
... the denaturation and hybridization steps in slide-based ... clinical and research personnel. The low cost ... types, is easy to use, and reduces ... ensuring overall precision and accuracy in all ...
... Pre-tested for optimal ... support the growth of ... for methylcellulose colony-forming assays ... hematopoietic cells. Not suitable ...
... description: Workstation for PCR set-up ... format to hold 0.2 ml PCR tubes, strips or ... automated handling systems Removable tray can be ... with V-bottom 0.2 ml tube block thermal cycler formats ...
... Mouse EL-4 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
Biology Products: